In conclusion, using a Bayesian hierarchical modelling approach, our systematic review and meta-analysis firstly revealed the overall incidences of treatment-related adverse events of HER2-targeted ADCs in patients with cancer in clinical trials. This evidence concerns the gene ERBB2 and cancer.